Exploratory trial to assess the efficacy and safety of Psilocybin-Assisted Psychotherapy (PAP) involving family-members compared to standard PAP, in adults with treatment-resistant major depressive disorder. (TRMDD)

This interventional trial (n=60) will assess the efficacy and safety of Psilocybin-Assisted Psychotherapy (PAP/PAT) involving family members in adults with treatment-resistant major depressive disorder (TRMDD). The study will compare two groups, one where PAT involves family members and another where PAT is conducted solely with therapists.

All participants will receive two doses of 25 mg of psilocybin three weeks apart. The primary outcome will be measured using the Hamilton Depression Rating Scale (HDRS) and the Montgomery–Åsberg Depression Rating Scale (MADRS) 12 months following the last psychotherapy session.

Trial Details



Trial Number

Sponsors & Collaborators

Reset Mind Science
Reset Mind Sciences, established in 2021, is a subsidiary of Little Green Pharma, a company known for its work in medicinal cannabis. Reset Mind Sciences is focused on producing and administering the psychedelic medication psilocybin derived from its in-house cultivated mushrooms​1​​.

University of Western Australia
The University of Western Australia (UWA) is a research and educational university. UWA's psychedelic research is connected to its alumnus Dr Shaun Duffy, a leading figure in this field in Australia.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.